Health Wildcatters — 2024 Investments
8 investments dated 2024 · listed companies and verified rows first · show all
ClearSight Therapeutics develops over-the-counter ophthalmic products for common eye conditions such as dry eye, contact lens dryness, and conjunctivitis, working within FDA OTC monograph pathways.
BiotechConsumerHealthtech
Patrick Smale(Cofounder & CEO)Suchismita Acharya(Cofounder & Clinical Development Lead)Nuria Jimenez(Chief Scientific Officer)
Co-investorsCapital Factory
Delta Robotics designs artificial muscle systems and a hardware-as-code validation platform for robotic applications.
AI & Machine LearningHardwareRobotics
Keyron develops ForePass, a fully endoscopic, non-invasive and reversible gastric bypass medical device intended to reproduce the effects of metabolic surgery for patients with Class II & III obesity, type 2 diabetes, MASH/NASH, and liver fibrosis.
BiotechHardwareMedical Devices
Giorgio Castagneto Gissey(Chief Executive, Chairman & Co-Founder)inJoyce Peetermans(Acting CTO)David Feigal(Head of Regulatory Affairs & Board Member)Francesco Rubino(Chief Officer for Obesity and Diabetes & Board Member)Carel le Roux(Chief Medical Officer & Director of Pharmaceutical Division)Nicol Verheem(Chief Investment Officer, Director of Diagnostics Division & Board Member)
MucoLife Therapeutics develops treatments for pulmonary mucus obstruction associated with chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF).
BiotechHealthtech
Thaher Pelaseyed(Co-founder & Chief Executive Officer)inGunnar C. Hansson(Co-founder & Chief Scientific Officer)inKicki Johansson(Chief Development Officer)inMaarten Kraan(Chief Clinical Officer)inJim Shaffer(Chief Business Officer)in
Rhythmm handles healthcare pre-authorization requests by combining AI-powered workflows with human specialists to accelerate insurance approvals and reduce denials for hospitals, clinics, and insurance networks.
AI & Machine LearningEnterprise SoftwareHealthtech
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
TeachMeNowTSP Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.